Schaper Benz & Wise Investment Counsel’s Matinas BioPharma MTNB Stock Holding History

Schaper Benz & Wise Investment Counsel’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-290	Closed	-$11K	–	140
2022 Q2	$11K	Hold	290	–	–	﹤0.01%	145
2022 Q1	$12K	Buy	290 +4	+1%	+$147	﹤0.01%	149
2021 Q4	$14K	Hold	286	–	–	﹤0.01%	147
2021 Q3	$19K	Hold	286	–	–	﹤0.01%	125
2021 Q2	$11K	Hold	286	–	–	﹤0.01%	128
2021 Q1	$15K	Hold	286	–	–	﹤0.01%	124
2020 Q4	$19K	Hold	286	–	–	﹤0.01%	125
2020 Q3	$11K	Hold	286	–	–	﹤0.01%	111
2020 Q2	$11K	Hold	286	–	–	﹤0.01%	109
2020 Q1	$9K	Hold	286	–	–	﹤0.01%	106
2019 Q4	$32K	Buy	+286	New	+$16.6K	﹤0.01%	111

Other funds holding MTNB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NRS

Neville Rodie & Shaw New York $1.55B AUM 46.95% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Schaper Benz & Wise Investment Counsel's MTNB Position: Q3 2022 in Review

Schaper Benz & Wise Investment Counsel sold out of Matinas BioPharma (MTNB) in Q3 2022, closing a stake of 290 shares — an estimated $11K sold.

Schaper Benz & Wise Investment Counsel first reported a position in MTNB in Q4 2019 and held it in 11 quarters. The position peaked at $32K in Q4 2019. 55 funds tracked by Wall St. Rank hold MTNB as of Q3 2022.

Schaper Benz & Wise Investment Counsel reported no remaining Matinas BioPharma position as of Q3 2022 after selling out during the quarter.
Schaper Benz & Wise Investment Counsel sold 290 Matinas BioPharma shares in Q3 2022, an estimated $11K.
Schaper Benz & Wise Investment Counsel first reported a position in Matinas BioPharma in Q4 2019 and held it in 11 quarters.
Schaper Benz & Wise Investment Counsel's Matinas BioPharma position peaked at $32K in Q4 2019.
55 funds tracked by Wall St. Rank held Matinas BioPharma as of Q3 2022.

Based on Schaper Benz & Wise Investment Counsel's 13F filing for Q3 2022, filed 17 Oct 2022.